We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for Core Laboratories (CLB) in Q4 Earnings?
Read MoreHide Full Article
Core Laboratories N.V. (CLB - Free Report) is scheduled to release fourth-quarter 2020 results on Wednesday Jan 27, after the closing bell.
The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is pegged at 15 cents while the same for revenues stands at $108.87 million.
Against this backdrop, let’s analyze the factors that might have impacted the company’s performance in the September quarter.
Factors at Play
Core Laboratories’ cost-reduction efforts have been raising investors’ optimism. In June 2020, the company had entered the second phase of its cost-cutting measures wherein the total annualized cost savings were estimated at $61 million.These cost-control measures are further expected to have driven the company’s fourth-quarter earnings and cash flows higher.
Additionally, Core Laboratories’ Production Enhancement segment is expected to have aided the company’s performance. The Zacks Consensus Estimate for the unit’s operating income, which is associated with the completion of wells, is pegged at $300,000. However, the segment reported an operating loss of $300,000 in the sequential quarter.
Meanwhile, the Zacks Consensus Estimate for the segment’s revenues is pegged at $27.05 million, suggesting an improvement from the sequential quarter’s reported figure of $25.32 million.
On the flip side, echoing the third-quarter trend, the continued coronavirus-led disruptions posed additional stumbling blocks to operators and service companies to cope with as well as induced extra expenses and operational incompetence during the fourth quarter.
Highlights of Q3 Earnings & Surprise History
In the last reported quarter, Core Laboratories’ adjusted earnings of 16 cents a share came ahead of the Zacks Consensus Estimate of 14 cents. This outperformance is attributable to lower year-over-year operating expenses, which declined to $94.1 million in the third quarter from $142 million in the year-ago period. However, the bottom line declined from the year-ago quarter’s earnings of 50 cents per share. This downside was caused by a drop in both international product sales and a ramped-down activity on international projects.
The oilfield service provider’s adjusted revenues of $105.38 million missed the Zacks Consensus Estimate of $109 million. Moreover, the top line fell from the year-ago quarter’s sales of $173.2 million.
As far as its earnings surprises are concerned, this Netherlands-based company’s bottom line outpaced the Zacks Consensus Estimate in two of the trailing four quarters, missing the same in one and meeting estimates on the remaining occasion, the average surprise being 15.26%. This is depicted in the graph below:
Our proven model does not conclusively predict an earnings beat for Core Laboratories this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of beating estimates. But that’s not the case here. You can uncover the best stocks to buy or sell before they’re reported with ourEarnings ESP Filter.
Earnings ESP: Core Laboratories has an Earnings ESP of -4.00%.
While earnings outperformance looks uncertain for Core Laboratories, here are some firms worth considering from the energy space on the basis of our model, which shows that these have the perfect combination of ingredients to deliver a beat this reporting cycle:
NuStar Energy L.P. (NS - Free Report) has an Earnings ESP of +21.21% and a Zacks Rank of 1, currently. The company is scheduled to release earnings on Feb 4.
PattersonUTI Energy, Inc. (PTEN - Free Report) has an Earnings ESP of +4.99% and is Zacks #3 Ranked, currently. The company is scheduled to release earnings on Feb 4.
Plains All American Pipeline, L.P. (PAA - Free Report) has an Earnings ESP of +32.81% and is a #3 Ranked stock, currently. The firm is scheduled to release earnings on Feb 9.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Image: Bigstock
What's in Store for Core Laboratories (CLB) in Q4 Earnings?
Core Laboratories N.V. (CLB - Free Report) is scheduled to release fourth-quarter 2020 results on Wednesday Jan 27, after the closing bell.
The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is pegged at 15 cents while the same for revenues stands at $108.87 million.
Against this backdrop, let’s analyze the factors that might have impacted the company’s performance in the September quarter.
Factors at Play
Core Laboratories’ cost-reduction efforts have been raising investors’ optimism. In June 2020, the company had entered the second phase of its cost-cutting measures wherein the total annualized cost savings were estimated at $61 million.These cost-control measures are further expected to have driven the company’s fourth-quarter earnings and cash flows higher.
Additionally, Core Laboratories’ Production Enhancement segment is expected to have aided the company’s performance. The Zacks Consensus Estimate for the unit’s operating income, which is associated with the completion of wells, is pegged at $300,000. However, the segment reported an operating loss of $300,000 in the sequential quarter.
Meanwhile, the Zacks Consensus Estimate for the segment’s revenues is pegged at $27.05 million, suggesting an improvement from the sequential quarter’s reported figure of $25.32 million.
On the flip side, echoing the third-quarter trend, the continued coronavirus-led disruptions posed additional stumbling blocks to operators and service companies to cope with as well as induced extra expenses and operational incompetence during the fourth quarter.
Highlights of Q3 Earnings & Surprise History
In the last reported quarter, Core Laboratories’ adjusted earnings of 16 cents a share came ahead of the Zacks Consensus Estimate of 14 cents. This outperformance is attributable to lower year-over-year operating expenses, which declined to $94.1 million in the third quarter from $142 million in the year-ago period. However, the bottom line declined from the year-ago quarter’s earnings of 50 cents per share. This downside was caused by a drop in both international product sales and a ramped-down activity on international projects.
The oilfield service provider’s adjusted revenues of $105.38 million missed the Zacks Consensus Estimate of $109 million. Moreover, the top line fell from the year-ago quarter’s sales of $173.2 million.
As far as its earnings surprises are concerned, this Netherlands-based company’s bottom line outpaced the Zacks Consensus Estimate in two of the trailing four quarters, missing the same in one and meeting estimates on the remaining occasion, the average surprise being 15.26%. This is depicted in the graph below:
Core Laboratories N.V. Price and EPS Surprise
Core Laboratories N.V. price-eps-surprise | Core Laboratories N.V. Quote
What Does Our Model Say?
Our proven model does not conclusively predict an earnings beat for Core Laboratories this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of beating estimates. But that’s not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter .
Earnings ESP: Core Laboratories has an Earnings ESP of -4.00%.
Zacks Rank: Core Laboratories carries a Zacks Rank #3, currently. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks to Consider
While earnings outperformance looks uncertain for Core Laboratories, here are some firms worth considering from the energy space on the basis of our model, which shows that these have the perfect combination of ingredients to deliver a beat this reporting cycle:
NuStar Energy L.P. (NS - Free Report) has an Earnings ESP of +21.21% and a Zacks Rank of 1, currently. The company is scheduled to release earnings on Feb 4.
PattersonUTI Energy, Inc. (PTEN - Free Report) has an Earnings ESP of +4.99% and is Zacks #3 Ranked, currently. The company is scheduled to release earnings on Feb 4.
Plains All American Pipeline, L.P. (PAA - Free Report) has an Earnings ESP of +32.81% and is a #3 Ranked stock, currently. The firm is scheduled to release earnings on Feb 9.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Click here for the 6 trades >>